Evidence map›Paper›PMID 33153826›Full record

ArticleAnais brasileiros de dermatologia

Consensus on the treatment of vitiligo - Brazilian Society of Dermatology.

Gerson Dellatorre, Daniela Alves Pereira Antelo, Roberta Buense Bedrikow, Tania Ferreira Cestari, Ivonise Follador, Daniel Gontijo Ramos, Caio Cesar Silva de Castro

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Vitiligo-Current Treatment Options and Future Perspectives.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Treatment Advances in Vitiligo: An Updated Review.Dermatology practical & conceptual · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. The Current Status of Antioxidants in the Treatment of Vitiligo in China.Oxidative medicine and cellular longevity · 2022
    Article
  12. Review
  13. Update on the pathogenesis of vitiligo.Anais brasileiros de dermatologia
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Gerson DellatorreDepartment of Dermatology, Hospital Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil.
Daniela Alves Pereira AnteloDepartment of Dermatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Roberta Buense BedrikowDepartment of Dermatology, Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil.
Tania Ferreira CestariDepartment of Dermatology, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Ivonise FolladorPrivate Clinic, Salvador, BA, Brazil.
Daniel Gontijo RamosDepartment of Dermatology, Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, MG, Brazil.
Caio Cesar Silva de CastroDepartment of Dermatology, Faculty of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil. Electronic address: caio.castro@pucpr.br.
Grupo Santa Casa de Belo Horizonte · BRHospital de Clínicas de Porto Alegre · BRIrmandade da Santa Casa de Misericórdia de São Paulo · BRPontifícia Universidade Católica do Paraná · BRUniversidade do Estado do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitiligo is a muco-cutaneous, autoimmune, localized, or disseminated disease, which manifests through hypochromic or achromic macules, with loss in quality of life. The prevalence of vitiligo in Brazil was determined to be 0.54%. There is no on-label medication for its treatment. To date, no Brazilian consensus on the treatment of vitiligo had been written.

objectivesThe objective of this group of Brazilian dermatologists with experience in the treatment of this disease was to reach a consensus on the clinical and surgical treatment of vitiligo, based on articles with the best scientific evidence.

methodsSeven dermatologists were invited, and each was assigned two treatment modalities to review. Each treatment (topical, systemic, and phototherapy) was reviewed by three experts. Two experts reviewed the surgical treatment. Subsequently, the coordinator compiled the different versions and drafted a text about each type of treatment. The new version was returned to all experts, who expressed their opinions and made suggestions for clarity. The final text was written by the coordinator and sent to all participants to prepare the final consensus. RESULTS/

conclusionThe experts defined the following as standard treatments of vitiligo: the use of topical corticosteroids and calcineurin inhibitors for localized and unstable cases; corticosteroid minipulse in progressive generalized vitiligo; narrowband UVB phototherapy for extensive forms of the disease. Surgical modalities should be indicated for segmental and stable generalized vitiligo. Topical and systemic anti-JAK drugs are being tested, with promising results.

Indexed as

DermatologyUltraviolet TherapyVitiligoBrazilHumansQuality of LifeTreatment OutcomeClinical protocolsCombined modality therapyConsensusTreatment outcomeVitiligo

Identifiers

PMID33153826
PMCPMC7772607
OpenAlexW3091942282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.